Search | Clinical Trials Finder

Conditions: Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
Interventions: darbepoetin alfa, pegfilgrastim, cisplatin, docetaxel, BNP7787; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 64
States / cities: Mountain View, California • Lewes, Delaware • Newark, Delaware + 42 more

Conditions: Lung Cancer
Interventions: epoetin alfa, carboplatin, paclitaxel, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Lung Cancer
Interventions: carboplatin, paclitaxel, sorafenib tosylate, radiation therapy; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Arlington, Texas • Dallas, Texas

Conditions: Lung Cancer
Interventions: panitumumab, carboplatin, paclitaxel, surgery; Drug · Procedure
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 31
States / cities: Carmichael, California • Sacramento, California • Colorado Springs, Colorado + 24 more

Conditions: Lung Cancer
Interventions: ras peptide cancer vaccine, sargramostim; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 17 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: cetuximab, paclitaxel, bevacizumab; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Colon, Cancer Skin, Cancer of Cervix, Cancer, Metastatic, Cancer of Larynx, Cancer of Neck, Cancer of Lung, Cancer of Brain and Nervous System, Cancer of Vulva, Disseminated, Cancer of Pancreas, Sarcoma, GIST, Small-cell Lung Cancer, Adenocarcinoma Lung, Cancer of Prostate, Cancer, Advanced, Adrenal Cancer, Testicular Cancer, Uterine Cancer, Bronchoalveolar Cell Lung Cancer, Cancer Unknown Primary, Glioblastoma Multiforme, Oligodendroglioma, Breast Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Cancer, Other, Cancer, Anal, Melanoma, Cancer, Bile Duct, Cancer, Bladder, Cancer Cords Vocal, Cancers Cell Neuroendocrine, Cancer Differentiated Poorly, Cancer, Anaplastic Thyroid
Interventions: Not listed
Lead sponsor: SpeciCare; Industry
Eligibility: 1 Month to 99 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Gainesville, Georgia

Conditions: Lung Cancer
Interventions: accelerated conformational radiotherapy; Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 20
States / cities: Fort Lauderdale, Florida • Hollywood, Florida • Jupiter, Florida + 15 more

Conditions: Lung Cancer
Interventions: carboplatin, paclitaxel, thalidomide, radiation therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 235
States / cities: Fort Smith, Arkansas • Modesto, California • Salinas, California + 168 more

Conditions: Lung Cancer
Interventions: lobectomy, segmentectomy or wedge resection; Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2025
U.S. locations: 373
States / cities: Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 244 more

Conditions: Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: bevacizumab, vandetanib, laboratory biomarker analysis, pharmacological study; Biological · Drug · Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: cisplatin, etoposide, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2013
U.S. locations: 15
States / cities: Urbana, Illinois • Indianapolis, Indiana • Cedar Rapids, Iowa + 10 more

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: cisplatin, pegfilgrastim, erlotinib hydrochloride, laboratory biomarker analysis, polymorphism analysis, pharmacogenomic studies, genetic linkage analysis, docetaxel; Drug · Biological · Other + 1 more
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Lung Cancer, Pulmonary Complications
Interventions: educational intervention, supervised exercise program; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 60
States / cities: Fort Collins, Colorado • Decatur, Illinois • Maywood, Illinois + 32 more

Conditions: Lung Cancer
Interventions: bevacizumab, vinorelbine tartrate; Biological · Drug
Lead sponsor: University of Rochester; Other
Eligibility: 70 Years to 120 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Lung Cancer, Bilateral Cancer, Lung Transplant
Interventions: Double Lung Transplantation; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma
Interventions: Akt Inhibitor MK2206, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Beverly Hills, California • Duarte, California • Los Angeles, California + 4 more

Conditions: Lung Cancer
Interventions: bevacizumab, erlotinib hydrochloride; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 148
States / cities: Antioch, California • Berkeley, California • Burlingame, California + 109 more

Conditions: Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm, Lung Non-Small Cell Squamous Carcinoma, Minimally Invasive Lung Adenocarcinoma, Neuroendocrine Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Large Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8
Interventions: Nivolumab, Stereotactic Body Radiation Therapy; Biological · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 3
States / cities: Conroe, Texas • Houston, Texas

Conditions: Lung Neoplasms, Carcinoma Non-small-cell Lung
Interventions: Multifocal Tissue Banking; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Cancer
Interventions: hypofractionated radiation therapy; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 2
States / cities: Stanford, California • Dallas, Texas

Conditions: Lung Cancer
Interventions: carboplatin, paclitaxel, radiation therapy; Drug · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 3
States / cities: Morristown, New Jersey • New Brunswick, New Jersey • Cleveland, Ohio

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: paclitaxel, carboplatin, gefitinib, radiation therapy, laboratory biomarker analysis; Drug · Radiation · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium; Drug · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 5
States / cities: Sacramento, California • Worcester, Massachusetts • The Bronx, New York

Search by objective public record fields.

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer

S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer And Lung Dysfunction

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer

Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies

MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing

Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer